Yep it's been a buzz word in testis cancer for a while now, but with the read-out of the CLIMATE and SWOG 1823 trials in the past six months, we thought we better get ourselves updated on this exciting biomarker.
We are joined in studio by testis cancer gurus Ben Tran (Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne), and online by Aditya Bagrodia (Urologist, UCSD, San Diego), to give us a bluffers guide to miR-371.
Plus we hear about the fantastic MaGIC Consortium global testis cancer meeting which takes place in Melbourne 8-11 January 2027. See links below. A great excuse to come to Melbourne, especially to escape the Northern Hemisphere winter!

Links:
MaGIC Consortium Conference, January 2027
Some coverage of the ANZUP CLIMATE trial from ASCO GU 2026
Some coverage of the SWOG 1823 trial from ASCO 2026

Welcome to Episode 8 of our monthly GU Cast Journal Club! Today we focus on two very important papers in localised prostate cancer and metastatic bladder cancer. The landmark 15 year update of the PROTECT trial, published in NEJM in 2023, and the breakthrough EV-301 trial which heralded enfortumab vedotin in progressive metastatic bladder cancer, published in NEJM in 2021.

We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Mexico City, MEX), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy.

Links to papers below:
1. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer NEJM 2023

2. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
NEJM 2021

Even better on our YouTube channel

About GU Cast Journal Club:
Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology
. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner
. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.

Renu had been to an excellent Bayer Apex meeting in Europe in the past, so was very happy to hear Apex was coming to us for its first Asia-Pacific outing! A wonderful prostate cancer Faculty headlined by Neal Shore, Dan George, Derya Tilki, Fred Saad, Amit Bahl, Tamim Niazi to name but a few, plus almost 200 delegates from across the APAC region.
Your usual hosts Renu Eapen and Declan Murphy catch up with some of the speakers and bring you conference highlights.
This is a Themed Podcast, supported by our Gold Partner, Bayer Pharmaceuticals.

Breaking News podcast just after the long-awaited PROTEUS trial reads out at the ASCO Plenary in Chicago! Plus a simultaneous NEJM paper! Huge day for prostate cancer surgery.
Declan and Renu are joined by lead author Dr Mary-Ellen Taplin (Dana Farber Cancer Institute & Harvard University), to tell us about her decades long journey to this huge moment today. PROTEUS is a huge (2,100 men) phase III RCT of men undergoing radical prostatectomy for high-risk prostate cancer, randomised to receive peri-operative ADT + placebo, or ADT plus apalutamide. Mary-Ellen talks to us about the top-line results, and we consider whether this is truly a practice-changing study. Declan also had the honour of being the Discussant at teh ASCO Plenary so he is well placed to give his opinion.
Your usual hosts are Declan Murphy & Renu Eapen.

Even better on our YouTube channel

This is a Themed Podcast supported by our Gold Partner, Johnson & Johnson.

Links:

PROTEUS NEJM paper

Two interesting papers caught the eye of our GU Cast China team this week; the first is the ARASEC trial which Dr Rana McKay read out in the Practice-Changing Plenary at the AUA Annual Meeting in Washington. This is an interesting comparison of ADT + darolutamide for mHSPC in a prospective US cohort, compared with an historical ADT-only control arm from CHAARTED. Interesting study design and interesting results.
The second is the ADT Lead-In study led bu GU Cast China Editor, Dr Yao Zhu, which demonstrates how the timing of docetaxel chemotherapy in mHSPC can significnatly affect the likelihood of severe neutropenia.
Your usual hosts, Declan Murphy and Renu Eapen, anre joined by Dr Yao Zhu (Fudan University, Shanghai), Dr Yige Bau (SCU Xiamen), and Dr Chuguan Yang (Tonji Hospital, Wuhan). Yige now also part of our GU Cast China team, looking after our We Chat content with Yao Zhu.
This is a Themed Podcast supported by our GU Cast China Partner, Bayer Pharmaceuticals.

Now this is an interesting one, a new PSMA tracer which appears to greatly outperform 68Ga-PSMA-11 for biochemical recurrence. We discuss 64Cu-SAR-bisPSMA with Professor Louise Emmett (Nuclear Medicine Physician, Sydney), and Dr Matt Roberts (Urologist, Brisbane), which they compared head to head with trusty old 68Ga-PSMA-11 in the Co-PSMA trial, just published in European Urology.

With usual hosts Declan Murphy and Renu Eapen.

This Themed Podcast is supported by our new Bronze Partners, Clarity Pharmaceuticals

Even better on our YouTube channel

Links:
Co-PSMA trial in European Urology

Clarity Pharmaceuticals website

One of our most popular podcasts every year is when we chat with EAU Guideline gurus Derya Tilki and Gianluca Giannarini about the latest updates to the EAU Prostate Cancer Guideline. It is a 250 word document which is updated in March every year and changes are eagerly awaited around the world.
We catch up with Derya (Vice Chair of the Prostate Cancer Guidleine Committee) in person in Melbourne, and with Gianluca (Vice-Chair of the EAU Guideline Office) online, about the latest updates. We also chat with Gianluca about the work of the Guideline Dissemination Committee which he has Chaired for a number of years.
With usual hosts Renu Eapen and Declan Murphy.

Supported by our Gold Partners, Bayer Pharmaceuticals.

Democracy in action! This month's GU Cast Journal Club papers were chosen by an audience vote at our GU Cast Live Event at EAU in London.
Therefore today we focus on first, the landmark proPSMA paper which established the superior accuracy of PSMA PET/CT for staging unfavourable intermediate and high-risk prostate cancer (Lancet 2020). Then for something completely different, we dig out a paper called "Penile fractures - the merry price of Christmas", published in BJUI 2020. Thanks very much to our live audience for this one!

We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado and Dr Elena Berg who joins us in studio for the first time. Elena has just moved to Melbourne to join Carlos doing a Fellowship with GU Cast hosts, Renu Eapen and Declan Murphy.

Links to papers below:
1. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020

2. Penile fractures: the price of a Merry Christmas BJUI 2023

GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.

Even better on our YouTube channel

About GU Cast Journal Club:
Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology
. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner
. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.